How Is Empagliflozin Working in Type 2 Diabetes in EMPA-REG?How Is Empagliflozin Working in Type 2 Diabetes in EMPA-REG?
Theories abound as to the mechanisms by which empagliflozin is reducing cardiovascular death and renal events in the EMPA-REG OUTCOME study; some of these were outlined at the recent ADA conference. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Conferences | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Study